BioSpace News Archive

Lone Star Bio

Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

Coya Therapeutics, Inc. today announced that Dr. Fred Grossman, President and Chief Medical Officer, is presenting at BTIG’s Virtual Biotechnology Conference 2023, Tuesday, August 8th at 1:30 p.m. ET.

August 3, 2023
·
5 min read
Drug Development

Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease

Celsius Therapeutics today announced the initiation of dosing in the company’s first-in-human Phase 1 clinical trial of CEL383 in healthy volunteers.

August 3, 2023
·
2 min read
Business

CareDx to Report Second Quarter 2023 Financial Results

CareDx, Inc. today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th , 2023.

August 3, 2023
·
1 min read
Drug Development

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma

Verrica Pharmaceuticals Inc. today announced the acceptance of an abstract that will feature clinical data from the Company’s ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma (“BCC”).

August 3, 2023
·
4 min read
Business

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported operational highlights and financial results for the second quarter ended June 30, 2023.

August 3, 2023
·
16 min read
Business

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2023, and provided recent business updates.

August 3, 2023
·
9 min read
Business

Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter ended June 30, 2023 and provided a corporate update.

August 3, 2023
·
17 min read
Business

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

Celcuity Inc. today announced that it will release its financial results for the second quarter 2023 after the stock market close on Thursday, August 10, 2023.

August 3, 2023
·
1 min read
Drug Development

Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

Bolt Biotherapeutics, Inc. today announced that the first patients have been dosed in a Phase 2 dose-expansion clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC).

August 3, 2023
·
6 min read
Business

Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

August 3, 2023
·
27 min read